DISRUPTIVE GENE THERAPY
TARGETING ROOT CAUSES OF SCARRING
FOR GLOBAL UNMET NEEDS IN SURGERY, TRAUMA AND BURN INJURIES
CELLASTRA'S GENE THERAPY REPORT 1 November 2019: Recent Approvals. IPOs and Aquisitions -
TOP GENE THERAPY COMPANIES
CELLASTRA INC 07/15/2019
Cellastra announces filing of global patent application for prevention of scars and adhesions.
CELLASTRA INC 06/24/2019
Cellastra announces collaboration with leading academic laboratory in Canada for manufacturing and testing of a novel gene vector programmed for scar prevention.
Preparing for clinical study in burn injuries
CELLASTRA INC 04/04/2019
Cellastra announces updates from American Burn Association's Annual Meeting in Las Vegas, April 2-5, 2019
Prof. Folke Sjoberg , Cellastra Scientific Advisory Board Memberawarded to give the Everett Idris Evans Memorial Lecture on frontiers in burn injury treatment
Cellastra prepares for clinical study in burn injury
ASSOCIATED PRESS 1/15/2019
FDA planning new guidance, hires in cell and gene therapies for 2019
The FDA plans to hire at least 50 new clinical reviewers tasked with assessing cell and gene therapies to prepare for what the agency describes as a surge of cutting-edge products currently entering early development.
The FDA predicts 10 to 20 cell and gene therapy approvals each year by2025. READ MORE
Cellastra announces 10M USD Series A capital call to support new gene therapy program for scar prevention after surgery and burn injuries
Appoints gene therapy leadership in new management positions READ MORE
Cellastra announces the appointment accounting veteran Bruce Phillips as new Chief Financial Officer. READ MORE
Cellastra announces acquisition of a novel gene therapy platform including global development and commercialization rights for scar prevention
First indication will be prevention of scarring and adhesions after surgery as well as burn injuries. Other indications to follow will include scar prevention after hip and knee replacement
One treatment may provide scar prevention for many months.